Erleada approved
FDA Approves Apalutamide (Erleada) fo... - Advanced Prostate...
FDA Approves Apalutamide (Erleada) for the Treatment of Metastatic Hormone-sensitive Prostate Cancer
Written by
6357axbz
To view profiles and participate in discussions please or .
2 Replies
•
This was probably posted previously. If so apologies for the redundancy. I’m wondering if this might reverse progression after abiraterone and adt fail. I don’t suppose anybody knows.
Not what you're looking for?
You may also like...
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Other triple therapy approved by the FDA. The article has the basic results of the ARASENS trial....
Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
Not surprising - question is the relative performance vs Abi or Enz (or combination with other...
Treatment options for metastatic prostate cancer?
My husband was diagnosed with metastatic prostate cancer in January 2022, his Gleason score is 9,...
Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
https://www.ascopost.com/issues/april-10-2019-supplement-conference-highlights-gugi-2019/interim-ana
Both apalutamide and enzalutamide succeed for metastatic hormone-sensitive prostate cancer (mHSPC) - enzalutamide not for high volume mets
New info presented this morning at ASCO - Enzalutamide (Xtandi) worked best in men with mHSPC with...
Related Posts
- FDA Approves First PARP Inhibitor Rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer
Metastatic prostate cancer 
prostate cancer metastatic
Metastatic Prostate Cancer- Two new advanced hormonal agents (apalutamide and enzalutamide) increase survival in metastatic hormone sensitive prostate cancer (mHSPC)
